ClinicalTrials.Veeva

Menu
S

Skin Cancer and Dermatology Institute | Reno - Moana Lane Location

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
AMG 451
IMG-007
Lunsekimig
BFB759
PH-762
Tapinarof
Camoteskimab
SAR443765
Ruxolitinib

Parent organization

This site is a part of Skin Cancer and Dermatology Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 17 total trials

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

Enrolling
Atopic Dermatitis
Eczema Atopic Dermatitis
Drug: Camoteskimab
Drug: Placebo

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB75...

Active, not recruiting
Atopic Dermatitis (AD)
Biological: BFB759
Drug: Placebo

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB75...

Active, not recruiting
Hidradenitis Suppurativa (HS)
Other: Placebo for BFB759
Biological: BFB759

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 2...

Active, not recruiting
Atopic Dermatitis
Drug: Vehicle Cream
Drug: Tapinarof cream, 1%

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period...

Active, not recruiting
Hidradenitis Suppurativa (HS)
Biological: Tibulizumab Dose B
Other: Placebo

Trial sponsors

Amgen logo
Genentech logo
B
A
Incyte logo
I
Insmed logo
Organon logo
P
Sanofi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems